samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > personalised medicine draws nearer
PUBLICATIONS
European Biopharmaceutical Review

Personalised Medicine Draws Nearer

What's your broad perspective on the uptake of pharmacogenomics to-date as a drug development activity, and how significant do you think this is for the industry? First of all, we have long believed that pharmacogenomics is really the first application of the genomics revolution. In other words, the first key products that will come out of the whole genomics field will be in the form of molecular diagnostics, based on determining genetic variability in patient response to drugs. We believe the pharmaceutical industry is now moving rapidly to incorporate pharmacogenomics across drug development activities. For example, in most clinical trials, DNA is being isolated and stored, to be queried later against genetic markers identifying which patients are responding to drugs.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Taylor Crouch joined Variagenics, Inc. in April 1999 with a distinguished track record in pharmaceutical marketing and clinical development. Formerly Senior Vice President for worldwide marketing and strategic development at the multinational CRO, PAREXEL International Corporation, he also spent 10 years in the pharmaceutical and device industries in new product development marketing at Schering Plough International, Pfizer International and Johnson & Johnson's Critikon Division. A man with a clear vision for the future of pharmacogenomics in the development and commercialisation of new medicines, Crouch spoke with Helen Abbott, Editor of EBR, about this brave new world.
spacer
Taylor Crouch
spacer
spacer
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avantorģ Enters into Distribution Agreement to Supply Agilent Technologiesí Chemistries and Supplies Division products in the U.S. and Canada

Enabling analytical chemistry workflow laboratories full access to Agilent Technologiesí Chemistries & Supplies Division (CSD) portfolio - focusing on chromatography columns, sample preparation products, chemical standards, and spectroscopy supplies through Avantorís leading digital and direct channels.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developerís mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement